Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iFIT myeloma treatment personalization trial
ISRCTN98606172Phase 3Recruiting
- Sponsor
- University of Leeds
- Start
- Jun 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial of daratumumab, lenalidomide, dexamethasone, teclistamab and talquetamab in multiple myeloma (MM) and plasma cell leukaemia (PCL), sponsored by University of Leeds. Primary endpoints: Progression-free survival, Event-free survival and 1 more. Started Jun 2026; status: recruiting.
02
Drugs
daratumumablenalidomidedexamethasoneteclistamabtalquetamab
03
Conditions
multiple myeloma (MM)plasma cell leukaemia (PCL)
Beyond the preview
Go deeper on ISRCTN98606172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN98606172.